Nov 4, 2025 07:00AM CervoMed gains FDA alignment for dementia with Lewy bodies drug trial

Oct 28, 2025 08:03AM CervoMed adds McKinsey veteran David Quigley to board of directors

Oct 8, 2025 07:00AM CervoMed reports positive Phase 2b trial results for dementia drug

Oct 7, 2025 08:01AM CervoMed names Matthew Winton as chief commercial and business officer

Aug 11, 2025 07:03AM CervoMed (CRVO) PT Raised to $15 at D. Boral Capital

Jul 29, 2025 07:20AM CervoMed (CRVO) PT Raised to $27 at Canaccord Genuity

Jul 28, 2025 07:01AM CervoMed reports positive 32-week trial data for dementia drug

May 13, 2025 06:20AM CervoMed (CRVO) Misses Q1 EPS by 56c

May 12, 2025 03:57PM Chardan Capital Markets Reiterates Buy Rating on CervoMed (CRVO)

Mar 13, 2025 11:23AM Jones Trading Upgrades CervoMed (CRVO) to Buy

Mar 12, 2025 04:39PM Chardan Capital Markets Upgrades CervoMed (CRVO) to Buy

Mar 11, 2025 08:20AM Brookline Capital Markets Upgrades CervoMed (CRVO) to Buy

Feb 19, 2025 07:05AM D. Boral Capital Upgrades CervoMed (CRVO) to Buy

Jan 31, 2025 08:03AM CervoMed (CRVO) Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

Dec 11, 2024 06:38AM CervoMed (CRVO) PT Lowered to $12 at Canaccord Genuity

Dec 11, 2024 05:19AM Morgan Stanley Downgrades CervoMed (CRVO) to Underweight

Dec 11, 2024 02:32AM Chardan Capital Markets Downgrades CervoMed (CRVO) to Neutral

Dec 10, 2024 11:37AM Brookline Capital Markets Downgrades CervoMed (CRVO) to Hold citing RewinD-LB Topline Data Failure

Dec 10, 2024 08:23AM D. Boral Capital Downgrades CervoMed (CRVO) to Hold

Dec 10, 2024 07:02AM CervoMed (CRVO) Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 6, 2024 08:43AM Roth/MKM Starts CervoMed (CRVO) at Buy

Nov 27, 2024 07:02AM CervoMed (CRVO) Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 18, 2024 07:16AM D. Boral Capital Starts CervoMed (CRVO) at Buy

Nov 13, 2024 08:00AM CervoMed (CRVO) Announces Key Senior Leadership Appointments

Nov 12, 2024 07:42AM CervoMed (CRVO) Misses Q3 EPS by 55c

Oct 3, 2024 05:15PM CervoMed (CRVO) Files $200M Mixed Shelf

Sep 18, 2024 05:17AM Chardan Capital Markets Starts CervoMed (CRVO) at Buy

Aug 12, 2024 09:51AM CervoMed (CRVO) Misses Q2 EPS by 27c

Jul 29, 2024 08:08AM CervoMed (CRVO) Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with DLB

Jul 26, 2024 03:45AM Morgan Stanley Starts CervoMed (CRVO) at Overweight

Jul 24, 2024 07:45AM BofA Securities Reiterates Buy Rating on Grupo Aeroportuario Del Sureste (ASURB:MM) (ASR), Top Pick

Jul 8, 2024 09:04AM Brookline Capital Markets Starts CervoMed (CRVO) at Buy